[{"uuid": "f2654434-387a-391c-be71-0f23b3627e4d", "title": "Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/precision-biosciences-strengthens-senior-leadership-120100438.html", "providerPublishTime": 1738152060, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/GLacIbS3fnPDWTs4O4sqCA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b17d69a2ca414fb27d5545572807a8c3", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/66zT56G2lAa70QEJSsgbOQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b17d69a2ca414fb27d5545572807a8c3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DTIL"]}, {"uuid": "3f08fefe-986e-3905-ab7a-c10dce8717e8", "title": "Precision BioSciences Shares Up After Upgrade From BMO Capital, Positive Date From Gene Therapy Study", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/precision-biosciences-shares-upgrade-bmo-201510982.html", "providerPublishTime": 1736540110, "type": "STORY", "relatedTickers": ["DTIL"]}, {"uuid": "2a314092-3791-3f1d-89d1-7f9c74576e6a", "title": "BMO Capital Upgrades Precision BioSciences to Outperform From Market Perform, Price Target is $34", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/bmo-capital-upgrades-precision-biosciences-141639952.html", "providerPublishTime": 1736518599, "type": "STORY", "relatedTickers": ["DTIL"]}, {"uuid": "dd6038c9-5ccd-30d3-a59d-0c8faa2d2639", "title": "Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/precision-biosciences-announces-complete-clinical-150100298.html", "providerPublishTime": 1736434860, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/NutlUzeFbYcxZ7C69CJRSw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/52ce5ab6f5fc6a9005b6dd0c6aace5f6", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Bs6brJvjvIHGOfGpE05z5g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/52ce5ab6f5fc6a9005b6dd0c6aace5f6", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DTIL"]}, {"uuid": "648ddba4-e967-35f0-8e8b-2762cdfe1b44", "title": "Top Midday Gainers", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/top-midday-gainers-181825561.html", "providerPublishTime": 1736533105, "type": "STORY", "relatedTickers": ["WBA"]}, {"uuid": "963aaa10-916e-3f42-ac9e-4905a3a0cdaf", "title": "Top Premarket Gainers", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/top-premarket-gainers-125042568.html", "providerPublishTime": 1736513442, "type": "STORY", "relatedTickers": ["AKYA", "VMAR"]}, {"uuid": "ffc7d881-b76d-3feb-bdeb-1cf82b103097", "title": "iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/iecure-reports-complete-clinical-response-130000299.html", "providerPublishTime": 1736427600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/1NPOyrw7e0Z431p8fBdZOw--~B/aD03MDU7dz0xODAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/80a43e75ae4c68c016d7fc6147736c8d", "width": 1800, "height": 705, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/QMnQ990l1Tikti5nGJNHHg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/80a43e75ae4c68c016d7fc6147736c8d", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DTIL"]}, {"uuid": "6416645d-43ee-3ba2-a113-bd7d47a2d3a2", "title": "Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/precision-biosciences-receives-approval-hong-120100591.html", "providerPublishTime": 1734523260, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/vrgaD_Pt49bwoCl_NBdEqw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab160baedd3ce978e40c2709d3dad7d3", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/BoTCEIAeDXJCU3bTK_HcjA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab160baedd3ce978e40c2709d3dad7d3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DTIL"]}, {"uuid": "0fa48e84-78cd-3c7e-a468-3aadcfe3f9d8", "title": "Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/0fa48e84-78cd-3c7e-a468-3aadcfe3f9d8/precision-gains-cta-approval.html", "providerPublishTime": 1734604977, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/2zrRGxKkmuoXtBK61iNuuQ--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/698ecfec26ebfb5b333aaea8cf493673", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/O59mwZoDluq5Xfbneg1SWQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/698ecfec26ebfb5b333aaea8cf493673", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DTIL"]}, {"uuid": "db6a0864-d091-3c17-915c-413094cf180a", "title": "Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/precision-biosciences-highlights-preclinical-data-120000262.html", "providerPublishTime": 1731672000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/mcMMK.RfJGNKdNFVBBesWQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/29ea110260d3a37f8202c23e968d9f26", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ZMg02DzJMLPimtyqOeQl9w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/29ea110260d3a37f8202c23e968d9f26", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DTIL"]}, {"uuid": "240f0238-1134-3d06-8403-fc2669fee0e3", "title": "Precision BioSciences to Participate in Upcoming November Investor Conferences", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/precision-biosciences-participate-upcoming-november-120100564.html", "providerPublishTime": 1732190460, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RlsQdnAOwtrOswf5S5jJwA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/eb4332a2c63f00279380d85acc6360d8", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HZ4dvsXA55.VDSzmIKo76A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/eb4332a2c63f00279380d85acc6360d8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DTIL"]}]